Diabetes Technology & Therapeutics

Papers
(The H4-Index of Diabetes Technology & Therapeutics is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes171
The Official Journal of ATTD Advanced Techologies & Treatments for Diabetes CONFERENCE 6–9 MARCH 2024 I FLORENCE & ONLINE149
Is It Time to Replace Time-in-Range with Time-in-Tight-Range? Maybe Not98
Statistically Adjusting for Wear Time in Randomized Trials of Continuous Glucose Monitors as a Complement to Intent-to-Treat and As-Treated Analyses: Application and Evaluation in Two Trials95
Practical Application of Continuous Glucose Monitoring in Clinical Practice: Case Studies72
Glycemia Around Exercise in Adults with Type 1 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A Switch Pilot Trial67
Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes63
Real-Life Achievements of MiniMed 780G Advanced Closed-Loop System in Youth with Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Trial62
Letter: Response to: “Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia”62
New Insulins, Biosimilars, and Insulin Therapy62
Impact of Sample Type on ADAP-Based Autoantibody Detection for Type 1 Diabetes Population Screening62
Acknowledgment of Reviewers 202561
Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility Study61
Disordered Eating Behaviors Among Adolescents and Young Adults with Type 1 Diabetes Treated with Insulin Pumps and Hybrid Closed-Loop Systems60
Developing and Evaluating a Natural Language Processing Algorithm to Detect Insulin Pump and Continuous Glucose Monitor Use in Electronic Health Records of Patients with Type 1 Diabetes57
Software Packages and Tools for the Analysis of Continuous Glucose Monitoring Data56
WITHDRAWN: Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial56
Decision Support Tool for Self-Management of Insulin Dosing in Type 1 Diabetes with Multiple Daily Injections: A Proof-of-Concept Study56
A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes55
A Randomized Crossover Pilot Study Evaluating Glucose Control During Exercise Initiated 1 or 2 h After a Meal in Adults with Type 1 Diabetes Treated with an Automated Insulin Delivery System55
Relationship Between Moderate-to-Vigorous Physical Activity and Glycemia Among Young Adults with Type 1 Diabetes and Overweight or Obesity: Results from the Advancing Care for Type 1 Diabetes and Obes53
A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor51
MiniMed TM 780G Hybrid Closed-Loop Systems Improves Markers of Vascular and Endothelial Function in Patients with Type 1 Diabetes: Association with C50
Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multicenter, Single-Arm, Feasibility Trial50
Glucose Predictions Improve Glycemic Control: A Digital Twin Evaluation49
MiniMed ™ 780G System Users Achieve Similar Glycemic Outcomes Regardless of Socioeconomic Disadvan47
Beyond the Coefficient of Variation: Reframing Glycemic Variability as Dispersion and Volatility43
Clinical Impact of Continuous Glucose Monitoring in Noninsulin Treated Type 2 Diabetes: A Review43
A Retrospective Real-Life Study to Compare Glycemic Control Between Simplified Meal Size Estimation and Precise Carbohydrates Counting in Type 1 Diabetes Patients Using DBLG1 Hybrid Closed-Loop System42
Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes41
Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States39
Practical Considerations and Implementation of Automated Insulin Delivery Systems38
A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes38
Metabolic Models, in Silico Trials, and Algorithms38
The Future of Dual Glucose–Ketone Monitoring in Youth with Diabetes37
Letter: Tirzepatide in Type 1 Diabetic Obese Patient Using Hybrid Closed-Loop36
0.29298496246338